Latest Insider Transactions at Fibrogen Inc (FGEN)
This section provides a real-time view of insider transactions for Fibrogen Inc (FGEN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of FIBROGEN INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of FIBROGEN INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 22
2021
|
Thane Wettig CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
620
-1.27%
|
$6,200
$10.18 P/Share
|
|
Sep 15
2021
|
Thomas F Kearns Jr Director |
SELL
Open market or private sale
|
Direct |
13,100
-24.78%
|
$144,100
$11.58 P/Share
|
|
Sep 07
2021
|
Juan Graham CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+49.02%
|
-
|
|
Sep 07
2021
|
Christine Chung SVP, CHINA OPERATIONS |
SELL
Payment of exercise price or tax liability
|
Direct |
2,030
-1.21%
|
$24,360
$12.41 P/Share
|
|
Sep 07
2021
|
Pat Cotroneo Executive Advisor & Former CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,141
-0.77%
|
$25,692
$12.41 P/Share
|
|
Aug 26
2021
|
Thane Wettig CEO |
BUY
Open market or private purchase
|
Direct |
3,100
+5.97%
|
$34,100
$11.53 P/Share
|
|
Jul 06
2021
|
Enrique A Conterno Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,859
-1.35%
|
$46,475
$25.06 P/Share
|
|
Jun 22
2021
|
Thane Wettig CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,593
-5.37%
|
$70,011
$27.65 P/Share
|
|
Jun 15
2021
|
Pat Cotroneo Executive Advisor & Former CFO |
SELL
Open market or private sale
|
Direct |
4,053
-1.44%
|
$101,325
$25.62 P/Share
|
|
Jun 07
2021
|
Christine Chung SVP, CHINA OPERATIONS |
SELL
Payment of exercise price or tax liability
|
Direct |
2,030
-1.21%
|
$44,660
$22.9 P/Share
|
|
Jun 07
2021
|
Pat Cotroneo Executive Advisor & Former CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,141
-0.76%
|
$47,102
$22.9 P/Share
|
|
May 26
2021
|
Suzanne Blaug |
BUY
Grant, award, or other acquisition
|
Direct |
4,700
+25.07%
|
-
|
|
May 26
2021
|
Aoife Brennan |
BUY
Grant, award, or other acquisition
|
Direct |
4,700
+35.3%
|
-
|
|
May 26
2021
|
Benjamin Cravatt |
BUY
Grant, award, or other acquisition
|
Direct |
4,700
+35.3%
|
-
|
|
May 26
2021
|
Jeffrey L Edwards |
BUY
Grant, award, or other acquisition
|
Direct |
4,700
+20.89%
|
-
|
|
May 26
2021
|
Jeffrey William Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,700
+20.89%
|
-
|
|
May 26
2021
|
Maykin Ho |
BUY
Grant, award, or other acquisition
|
Direct |
4,700
+22.75%
|
-
|
|
May 26
2021
|
Thomas F Kearns Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,700
+8.16%
|
-
|
|
May 26
2021
|
Kalevi Kurkijarvi Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,700
+11.06%
|
-
|
|
May 26
2021
|
Gerald Lema |
BUY
Grant, award, or other acquisition
|
Direct |
4,700
+33.33%
|
-
|
|
May 26
2021
|
Rory B Riggs Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,700
+1.17%
|
-
|
|
May 26
2021
|
James A Schoeneck |
BUY
Grant, award, or other acquisition
|
Direct |
4,700
+25.0%
|
-
|
|
Mar 11
2021
|
Thomas F Kearns Jr Director |
SELL
Open market or private sale
|
Direct |
18,000
-10.83%
|
$630,000
$35.02 P/Share
|
|
Mar 11
2021
|
Thomas F Kearns Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
18,000
+9.77%
|
$54,000
$3.5 P/Share
|
|
Mar 08
2021
|
Christine Chung SVP, CHINA OPERATIONS |
SELL
Payment of exercise price or tax liability
|
Direct |
5,679
-3.3%
|
$187,407
$33.37 P/Share
|
|
Mar 08
2021
|
Pat Cotroneo Executive Advisor & Former CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,657
-1.97%
|
$186,681
$33.37 P/Share
|
|
Mar 08
2021
|
Elias Kouchakji SVP, Clinical Dev, Drug Safety |
SELL
Payment of exercise price or tax liability
|
Direct |
5,221
-3.42%
|
$172,293
$33.37 P/Share
|
|
Feb 24
2021
|
Enrique A Conterno Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
82,000
+37.4%
|
-
|
|
Feb 24
2021
|
Christine Chung SVP, CHINA OPERATIONS |
BUY
Grant, award, or other acquisition
|
Direct |
21,700
+11.19%
|
-
|
|
Feb 24
2021
|
Pat Cotroneo Executive Advisor & Former CFO |
BUY
Grant, award, or other acquisition
|
Direct |
21,700
+7.01%
|
-
|
|
Feb 24
2021
|
Elias Kouchakji SVP, Clinical Dev, Drug Safety |
BUY
Grant, award, or other acquisition
|
Direct |
20,800
+12.0%
|
-
|
|
Feb 24
2021
|
Thane Wettig CEO |
BUY
Grant, award, or other acquisition
|
Direct |
16,500
+25.92%
|
-
|
|
Feb 17
2021
|
Kalevi Kurkijarvi Director |
SELL
Open market or private sale
|
Direct |
6,000
-7.84%
|
$312,000
$52.62 P/Share
|
|
Feb 17
2021
|
Kalevi Kurkijarvi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+13.3%
|
$168,000
$28.65 P/Share
|
|
Jan 19
2021
|
Kalevi Kurkijarvi Director |
SELL
Open market or private sale
|
Direct |
6,000
-15.35%
|
$258,000
$43.38 P/Share
|
|
Jan 19
2021
|
Kalevi Kurkijarvi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+13.3%
|
$114,000
$19.05 P/Share
|
|
Jan 14
2021
|
Kalevi Kurkijarvi Director |
SELL
Open market or private sale
|
Direct |
5,999
-15.34%
|
$239,960
$40.04 P/Share
|
|
Jan 14
2021
|
Kalevi Kurkijarvi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,999
+13.3%
|
$113,981
$19.05 P/Share
|
|
Jan 06
2021
|
Enrique A Conterno Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,411
-8.92%
|
$205,618
$38.31 P/Share
|
|
Jan 04
2021
|
James A Schoeneck |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+28.04%
|
$54,000
$9.78 P/Share
|
|
Dec 28
2020
|
Kalevi Kurkijarvi Director |
SELL
Open market or private sale
|
Direct |
6,001
-7.7%
|
$240,040
$40.76 P/Share
|
|
Dec 28
2020
|
Kalevi Kurkijarvi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,001
+6.65%
|
$108,018
$18.7 P/Share
|
|
Dec 16
2020
|
K Peony Yu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,350
-1.71%
|
$137,350
$41.61 P/Share
|
|
Dec 15
2020
|
Pat Cotroneo Executive Advisor & Former CFO |
SELL
Open market or private sale
|
Direct |
3,068
-1.14%
|
$131,924
$43.6 P/Share
|
|
Dec 07
2020
|
Christine Chung SVP, CHINA OPERATIONS |
SELL
Payment of exercise price or tax liability
|
Direct |
3,039
-1.98%
|
$124,599
$41.99 P/Share
|
|
Dec 07
2020
|
Pat Cotroneo Executive Advisor & Former CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,014
-1.11%
|
$123,574
$41.99 P/Share
|
|
Dec 07
2020
|
Elias Kouchakji SVP, Clinical Dev, Drug Safety |
SELL
Payment of exercise price or tax liability
|
Direct |
2,728
-2.03%
|
$111,848
$41.99 P/Share
|
|
Dec 07
2020
|
K Peony Yu Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,292
-1.65%
|
$134,972
$41.99 P/Share
|
|
Dec 01
2020
|
Mark Eisner EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+50.0%
|
-
|
|
Nov 17
2020
|
Elias Kouchakji SVP, Clinical Dev, Drug Safety |
BUY
Exercise of conversion of derivative security
|
Direct |
7,082
+5.0%
|
$99,148
$14.57 P/Share
|